Seres Therapeutics, Inc.(MCRB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,925 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in MCRB
Events flagged as statistical outliers against MCRB's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-16
MCRB quality score jumped 13 points (10→23) on a new filing
View source filing →
MCRB Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Seres Therapeutics, Inc. (MCRB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MCRB at 8.8/100 on a 32-signal composite quality model, placing it at rank #2,925 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (0.7) and free cash flow (1.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Seres Therapeutics, Inc. reports quarterly revenue of $736.0K, net income of $4.6M, free cash flow of $-22.4M. Top institutional holders of MCRB by reported 13-F value include Flagship Pioneering, VANGUARD CAPITAL MANAGEMENT, MARSHALL WACE, LLP, based on the most recent SEC filings. MCRB trades on the Nasdaq exchange and files with the SEC under CIK 1609809. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MCRB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Seres Therapeutics, Inc. directly from SEC EDGAR. Seres Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 7 and 50 since 2021, currently 8.8 — a stable long-term trajectory across 53 quarterly and live scoring snapshots.
Revenue
Q2 2026
$736.0K
Net Income
Q2 2026
$4.6M
Free Cash Flow
Q2 2026
$-22.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+4088.2% YoYOperating Income
+22.5% YoYEPS (Diluted)
Total Assets
-1.2% YoYTotal Debt
Op. Cash Flow
+100.8% YoYFree Cash Flow
+100.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $789.0K | $0.00 | $0.00 -100.0% | $7.1M -95.1% | $144.9M +336.3% | $33.2M |
| Net Income | $5.7M +4088.2% | $136.0K +100.1% | $-113.7M +54.5% | $-250.2M -281.5% | $-65.6M +26.4% | $-89.1M |
| Operating Income | $-94.0M +22.5% | $-121.3M +37.8% | $-195.1M -8.4% | $-179.9M -179.0% | $-64.5M +26.8% | $-88.1M |
| EPS (Diluted) | $0.64 | $0.00 +100.0% | $-0.89 -669.3% | $-0.12 -220.8% | $-0.04 +35.7% | $-0.06 |
| Total Assets | $138.2M -1.2% | $139.8M -61.0% | $358.6M +2.8% | $348.8M -1.7% | $354.9M +3.5% | $342.9M |
| Total Debt | — | — | $110.0M +120.0% | $50.0M +107.9% | $24.1M -3.8% | $25.0M |
| Operating Cash Flow | $1.1M +100.8% | $-148.6M -26.6% | $-117.4M +48.7% | $-228.8M -3521.3% | $6.7M +107.1% | $-93.6M |
| Free Cash Flow | $865.0K +100.6% | $-149.0M -18.9% | $-125.3M +47.5% | $-238.6M -8191.8% | $-2.9M +96.9% | $-94.2M |
Get alerted when MCRB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Seres Therapeutics, Inc. including:
Top Institutional Holders of MCRB
Flagship Pioneering Inc.
$9.1M1,155,850 shVANGUARD CAPITAL MANAGEMENT LLC
$2.3M287,776 shMARSHALL WACE, LLP
$1.4M172,245 shVontobel Holding Ltd.
$970.3K122,975 shBlackRock, Inc.
$875.8K111,000 shGEODE CAPITAL MANAGEMENT, LLC
$631.3K79,974 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$503.4K63,800 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$460.2K58,328 shVANGUARD FIDUCIARY TRUST CO
$384.1K48,685 shCITADEL ADVISORS LLC
$343.2K43,500 sh
| Fund | Value | Shares |
|---|---|---|
| Flagship Pioneering Inc. | $9.1M | 1,155,850 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.3M | 287,776 |
| MARSHALL WACE, LLP | $1.4M | 172,245 |
| Vontobel Holding Ltd. | $970.3K | 122,975 |
| BlackRock, Inc. | $875.8K | 111,000 |
| GEODE CAPITAL MANAGEMENT, LLC | $631.3K | 79,974 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $503.4K | 63,800 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $460.2K | 58,328 |
| VANGUARD FIDUCIARY TRUST CO | $384.1K | 48,685 |
| CITADEL ADVISORS LLC | $343.2K | 43,500 |
Companies Similar to MCRB
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Humacyte, Inc.
Keros Therapeutics, Inc.
IDEAYA Biosciences, Inc.
SERA PROGNOSTICS, INC.
Arcturus Therapeutics Holdings Inc.
uniQure N.V.
Streamex Corp.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put MCRB on your watchlist
Track score changes the day Seres Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MCRB a good stock to buy?
13F Pro's AI-powered analysis of Seres Therapeutics, Inc. (MCRB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MCRB are available on the MCRB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MCRB is classified as a small company.
Which hedge funds own MCRB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MCRB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Seres Therapeutics, Inc.'s investment landscape.